A 50-year-old man presented to clinic with a two-year history of progressive exertional dyspnea and voice hoarseness. This history suggested upper airways obstruction, which was confirmed on computed tomography imaging that revealed extensive thickening of the proximal tracheal wall causing severe luminal narrowing. Bronchoscopic debulking was then performed and the samples obtained confirmed tracheal amyloidosis. Extensive investigation confirmed that disease was localized solely to the trachea. Ultimately, after multiple discussions, the chosen treatment modality was radiotherapy, which proceeded relatively uneventfully and achieved excellent radiological and clinical response. Although tracheal amyloidosis is rare, it is most commonly observed as part of a multisystem presentation. The present report describes the even more uncommon diagnosis of isolated tracheal amyloidosis and highlights the role of radiotherapy in its management.

Key Words: Tracheal amyloid; Tracheal radiotherapy; Stridor


A rare cause of stridor: Isolated tracheal amyloidosis

Une cause rare de stridor : l’amylose trachéale isolée

Un homme de 50 ans s’est rendu à la clinique parce que, depuis deux ans, il faisait de la dyspnée à l’effort allant en s’aggravant et que sa voix devenait raque. Ses antécédents laissaient supposer une obstruction des voies aériennes supérieures, confirmée par une tomodensitométrie qui a révélé un important épaississement de la paroi proximale de la trachée, responsable d’un rétrécissement marqué de la lumière. Une réduction bronchoscopique a confirmé l’amylose trachéale. Des examens approfondis ont également confirmé une atteinte limitée à la trachée. Après plusieurs discussions, la radiothérapie a été retenue comme modalité de traitement, laquelle s’est déroulée relativement sans incident et a suscité une excellente réponse radiologique et clinique. L’amylose trachéale est rare, mais on l’observe surtout en présentation multisyndrôme. Le présent rapport décrit le diagnostic encore plus rare d’amylose trachéale isolée et souligne le rôle de la radiothérapie pour la prise en charge.

Learning objectives

- To be aware that amyloidosis can occur as an isolated tracheal disease.
- To recognize the roles of interventional bronchoscopy and radiotherapy in the management of tracheal amyloidosis.

CanMeds Competency: Medical Expert Collaborator

Pretest

- What management options can be considered for tracheal amyloidosis?

CASE PRESENTATION

A 50-year-old man presented to the respiratory clinic with a two-year history of vocal hoarseness and slowly progressive exertional dyspnea. He was able to work and run, but also reported four months of ‘noisy’ breathing, particularly on exertion. He was otherwise fit, an ex-smoker history of vocal hoarseness and slowly progressive exertional dyspnea. He was able to work and run, but also reported four months of ‘noisy’ breathing, particularly on exertion. He was otherwise fit, an ex-smoker

1Department of Respiratory Medicine, Churchill Hospital, Oxford; 2Horton Hospital, Banbury, England, United Kingdom
Correspondence: Dr Numbere K Numere, Department of Respiratory Medicine, Churchill Hospital, Old Road, Headington, Oxford, England OX3 7LE, United Kingdom. Telephone 44-776-049-6152; e-mail numbere@doctors.org.uk

©2014 Pulsus Group Inc. All rights reserved
on inspection. Extensive mechanical debulking was performed in the middle trachea, where disease involvement had caused significant luminal narrowing. Hemostasis was achieved using argon plasma coagulation where necessary. The bronchoscope was replaced with a suspension laryngoscope through which the patient continued to be jet ventilated. A Diego microdebrider (Olympus, Japan) was introduced via the laryngoscope, which was successfully used to restore luminal patency at a subglottic level. By the end of the procedure, an essentially normal-calibre lumen was restored – this is demonstrated radiologically in Figure 3. Stenting was not performed because any stent would have had to be very high and close to the cords given his disease extent. This could create speech problems and could also lead to granuloma formation, a potential cause of stenosis above a stent. Another reason not to stent was that there was, and still is, uncertainty about the natural history of the disease, particularly in a relatively young man.

He was subsequently referred to the National Amyloidosis Centre in Royal Free Hospital (London, United Kingdom), where a battery of investigations were performed and confirmed that this was, in fact, isolated spontaneous localized amyloidosis. These included a normal immunoglobulin screen, a negative myeloma screen, a normal echocardiogram and normal serum amyloid P scintigraphy with no visceral uptake.

After extensive discussions regarding long-term management approaches including recurrent debulking with risk of stricture formation, tracheostomy and stenting, it was decided to proceed with radiotherapy, 20 Gy in 10 fractions. The patient completed the course and the only side effect was mild odynophagia due to esophagitis. He reported further improvement in voice and fitness postradiotherapy.

An interval scan 12 months after completion of radiotherapy showed no disease progression and the patient remained asymptomatic, with normal spirometry and flow-volume loops 14 months after radiotherapy.

**DISCUSSION**

Amyloidosis is a disease characterized by the deposition of fibrillary protein amyloid in the extravascular spaces causing insidious, progressive damage to tissues and organs. The term ‘amyloid’ is derived from the Latin ‘amylum’, referring to starch and was first used to describe this substance by German doctor and pathologist Rudolf Virchow. Amyloid had been encountered previously, but Virchow noted an interaction between iodine and cerebral tissue samples from patients with cerebral amyloidosis and named it on the assumption that it was structurally related to starch (1).

The diagnosis is based on the isolation and identification of amyloid protein in tissue biopsied from an affected organ and appropriate staining (eg, Congo red). There are >20 types of amyloid protein identified that can cause a wide variety of clinical presentations, broadly divided into systemic and localized amyloidosis (2).

Pulmonary involvement in systemic amyloidosis occurs mainly with systemic amyloid light-chain disease and is usually asymptomatic. Smith et al (3) reported that 88% of patients with systemic amyloid disease had pulmonary involvement postmortem. Utz et al (4) found 35 of 55 pulmonary amyloid patients had systemic disease. There are four main patterns of isolated amyloid of the respiratory tract: infiltrative parenchymal amyloidosis, rare because it is usually associated with systemic amyloidosis; nodular parenchymal amyloid, which rarely requires treatment; tracheobronchial amyloid, which can be diffuse or nodular (5); and finally, pseudotumour tracheobronchial amyloid, which has the appearance of a discrete tumour (6). In 1983, Thompson and Citron (7) identified 126 cases of localized primary pulmonary amyloid, 57 of which had tracheobronchial disease, 55 had nodular parenchymal disease, 10 had pseudotumour disease and four had diffuse parenchymal involvement (7). More recently, a case series involving patients with amyloid with isolated respiratory system involvement demonstrated that of 11 patients with isolated primary pulmonary disease, seven had tracheobronchial amyloid, three had nodular parenchymal disease and one had diffuse parenchymal disease (8).

Fewer than 200 cases of primary isolated tracheobronchial amyloid have been identified, and isolated diffuse infiltrative tracheal amyloidosis is even more rare (9-12). It is, as demonstrated in the present case, of great importance to exclude involvement of other systems to determine prognosis and plan management. The bronchoscopic appearance can vary from diffuse confluent disease in the present case to nodular
deposition; presenting symptoms vary including cough, hemoptysis and, in extreme cases such as this, stridor (2,3). The vast majority of cases are histologically amyloid light-chain type (13).

The present patient experienced a gradual deterioration after bronchoscopy, which is unusual for airway edema postbronchoscopy; intravenous dexamethasone was administered before the procedure. His decline was likely unrelated to his bronchoscopy, especially in the context of radiological evidence of progressive disease. Because this patient ultimately presented after diagnosis as an emergency, his initial management was surgical: bronchoscopic laser photocoagulation and manual debulking. Beyond repeated bronchoscopic intervention, more radical long-term surgical options include stenting with simple stents or Y stents depending on disease extent; tracheostomy formation to bypass diseased trachea in cases of rapidly progressive infiltrative amyloid; and finally, resection of short tracheal segments in localized pseudounion disease (14). Stem cell tracheal transplantation is an area of some excitement because it may provide an additional treatment option in the future (15). Surgical options are, however, always limited by risk of bleeding given the friable nature of amyloid as well as a potential need for recurrent procedures with a theoretical risk of ultimately leading to stricture formation (16). It is for this reason that radiotherapy was used as a consolidation treatment with the aims of not only causing disease regression and symptomatic relief but also of reducing the need for recurrent invasive surgery.

The body of evidence supporting radiotherapy is limited and includes a handful of case reports and one case series (17-20). A 2007 case series investigated seven patients, all given 20 Gy in 10 fractions, with a follow-up period ranging from 10 to 69 months (20). All patients had favourable responses, with five reporting improvement in their symptoms and two reporting no symptom progression during the follow-up period. The authors go as far as recommending radiotherapy as the primary treatment modality in cases of symptomatic bulky disease where bronchoscopic recanalization is not possible. This was based on the premise that although there are potential risks, such as radiation pericarditis, esophagitis and pneumonitis, their data suggested radiotherapy may, in fact, change the disease course because there was no symptom recurrence through a relatively long follow-up period. Interestingly, they also noted that forced expiratory volume in 1 s and flow-volume loops did not correlate well with symptomatic improvement. There may also be a role for radiotherapy in primary pulmonary nodular amyloidosis, as detailed in a recent case report (21).

The literature on isolated tracheobronchial amyloid is, on the whole, sparse, particularly in terms of follow-up data; consequently, there are no concrete prognostic data. Survival has been linked to degree of respiratory impairment and extent of disease, with more proximal disease being a poor prognostic marker (22).

The present case illustrates that amyloidosis can present as isolated tracheal disease causing symptomatic tracheal narrowing. We have also reported that radiotherapy is a viable noninvasive treatment modality that should be considered and implemented early in symptomatic cases.

**Post-test**

- What management options can be considered for tracheal amyloidosis?

Management options for symptomatic isolated tracheal amyloidosis include repeated bronchoscopic debulking or laser photocoagulation, stenting, radiotherapy, segmental tracheal resection, tracheostomy formation or, potentially, tracheal transplantation. Radiotherapy is a relatively accessible treatment modality that, unlike other options, may change the disease course and has an acceptable side-effect profile. Thus, its use should be considered in the management of this disease and, consequently, cases should be discussed in a multidisciplinary setting with respiratory physicians, thoracic surgeons, radiologists and clinical oncologists.

**DISCLOSURES:** The authors have no financial disclosures or conflicts of interest to declare.
Submit your manuscripts at http://www.hindawi.com